MPLT
MapLight Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.71
−1.47%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$6.80
From 52W high−83.14%
Volume388883.00
Market cap$372.91M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$6.80
From 52W high
−83.14%
Volume
388883.00
Market cap
$372.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
25.3
MomentumView details →
1D Return
−1.47%
YTD Return
−62.32%
Similar companies
Latest newsMore news →
MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.83d agoMapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.83d agoMapLight Therapeutics announced a private placement financing (PIPE) to raise approximately $150 million in gross proceeds from institutional and accredited investors.83d ago